Skip to main content
Advertisement
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
ADVERTISEMENT
Douglas Wolf
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study
BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...
Stephen B. Hanauer , MD;
Michael Silver ;
Brian G. Feagan ;
Raymond Cross , MD;
David Hudesman , MD;
Douglas Wolf ;
Millie D. Long , MD, MPH;
Subrata Ghosh ;
AnnKatrin Petersen ;
Marc Pondel ;
12/15/2021
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively targets S1P 1 and S1P ...
Raymond Cross , MD;
Jonathan Calkwood ;
Ashwini Pai ;
Millie D. Long , MD, MPH;
Ayanbola Elegbe ;
James Sheffield ;
Douglas Wolf ;
Adil Javed ;
AnnKatrin Petersen ;
Marc Pondel ;
Lorna Charles ;
Harris A. Ahmad ;
12/15/2021
P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
BACKGROUND: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P 1 and S1P ...
Remo Panaccione ;
Douglas Wolf ;
AnnKatrin Petersen ;
Marc Pondel ;
Bruce E. Sands , MD, MS;
Michael Silver ;
Edward V. Loftus Jr., MD;
Jean-Frederic Colombel ;
Andreas Sturm ;
Geert D'Haens ;
12/15/2021
Featured Webinar
Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications
Advertisement
Advertisement
Advertisement
Advertisement
Upcoming Events
November 23 – November 24
December 4 – December 5
December 6 – December 7
December 9 – December 11
December 9 – December 11
December 12 – December 13
December 14 – December 15
February 2 – February 5
February 27 – March 1
March 17 – March 19
See Full Calendar
Advertisement
Advertisement
Advertisement